Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.09
BASI's Cash to Debt is ranked lower than
94% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.70 vs. BASI: 0.09 )
Ranked among companies with meaningful Cash to Debt only.
BASI' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.09 Max: N/A
Current: 0.09
Equity to Asset 0.43
BASI's Equity to Asset is ranked lower than
74% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.62 vs. BASI: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
BASI' s Equity to Asset Range Over the Past 10 Years
Min: 0.31  Med: 0.44 Max: 0.83
Current: 0.43
0.31
0.83
F-Score: 4
Z-Score: 0.06
M-Score: -2.97
WACC vs ROIC
3.89%
-0.44%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -0.24
BASI's Operating margin (%) is ranked lower than
51% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.99 vs. BASI: -0.24 )
Ranked among companies with meaningful Operating margin (%) only.
BASI' s Operating margin (%) Range Over the Past 10 Years
Min: -20.16  Med: 2.56 Max: 6.7
Current: -0.24
-20.16
6.7
Net-margin (%) 0.03
BASI's Net-margin (%) is ranked higher than
51% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.63 vs. BASI: 0.03 )
Ranked among companies with meaningful Net-margin (%) only.
BASI' s Net-margin (%) Range Over the Past 10 Years
Min: -22.65  Med: -3.96 Max: 4.84
Current: 0.03
-22.65
4.84
ROE (%) 0.07
BASI's ROE (%) is ranked higher than
54% of the 185 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.04 vs. BASI: 0.07 )
Ranked among companies with meaningful ROE (%) only.
BASI' s ROE (%) Range Over the Past 10 Years
Min: -56.36  Med: -12.69 Max: 10.85
Current: 0.07
-56.36
10.85
ROA (%) 0.03
BASI's ROA (%) is ranked higher than
57% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.78 vs. BASI: 0.03 )
Ranked among companies with meaningful ROA (%) only.
BASI' s ROA (%) Range Over the Past 10 Years
Min: -21.54  Med: -3.97 Max: 4.62
Current: 0.03
-21.54
4.62
ROC (Joel Greenblatt) (%) 1.84
BASI's ROC (Joel Greenblatt) (%) is ranked higher than
55% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.88 vs. BASI: 1.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BASI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -29.08  Med: 1.51 Max: 9.98
Current: 1.84
-29.08
9.98
Revenue Growth (3Y)(%) -13.10
BASI's Revenue Growth (3Y)(%) is ranked lower than
79% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. BASI: -13.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BASI' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -23.4  Med: -1.55 Max: 14.9
Current: -13.1
-23.4
14.9
» BASI's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-13)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

BASI Guru Trades in Q2 2015

Jim Simons 12,400 sh (+19.23%)
» More
Q3 2015

BASI Guru Trades in Q3 2015

Jim Simons 14,600 sh (+17.74%)
» More
Q4 2015

BASI Guru Trades in Q4 2015

Jim Simons 15,500 sh (+6.16%)
» More
Q1 2016

BASI Guru Trades in Q1 2016

Jim Simons 17,000 sh (+9.68%)
» More
» Details

Insider Trades

Latest Guru Trades with BASI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:ATOS, TSXV:IDL, NAS:GBSN, OTCPK:OXIS, ASX:DXB » details
Traded in other countries:BS5.Germany,
Bioanalytical Systems Inc is a contract research organization providing drug discovery and development services and analytical instruments. Its customers and partners include pharmaceutical, biotechnology, academic and government organizations.

Bioanalytical Systems Inc is a corporation organized in Indiana in 1974. The Company is a contract research organization providing drug discovery and development services and analytical instruments. Its clients and partners include pharmaceutical, biotechnology, academic and government organizations. It supports the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. The Companys principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research from small start-up biotechnology companies to many of the largest global pharmaceutical companies. The drug discovery and development process is heavily regulated by the FDA and its Center for Drug Evaluation and Research. It operates in two business segments contract research services and research products, both of which address the bioanalytical, preclinical, and clinical research needs of drug developers. The contract research services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance and quality control testing. The services provided by its contract research services segment include Product Characterization, Method Development and Validation, Bioanalytical Testing, Stability Testing, In Vivo Pharmacology, and Preclinical and Pathology Services. The products business targets life science research and designs, develops, manufactures and markets Analytical Products, In vivo Sampling Products, Vetronics Products. It promotes its services through concentrated business development efforts, scientist-to-scientist communications and centralized corporate marketing programs. The Company competes with in-house research, development, quality control and other support service departments of pharmaceutical and biotechnology companies. Its competitors include Covance, Inc., Pharmaceutical Product Development, Inc., Charles River Laboratories, Inc., Quintiles Transnational Holdings, Inc. The Company is subject to various regulatory requirements designed to ensure the quality and integrity of its data and products.

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 9.19
BASI's Price/Owner Earnings (ttm) is ranked higher than
95% of the 57 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.47 vs. BASI: 9.19 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BASI' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 3.31  Med: 18.75 Max: 395.71
Current: 9.19
3.31
395.71
P/B 0.97
BASI's P/B is ranked higher than
93% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.08 vs. BASI: 0.97 )
Ranked among companies with meaningful P/B only.
BASI' s P/B Range Over the Past 10 Years
Min: 0.23  Med: 1.40 Max: 3.22
Current: 0.97
0.23
3.22
P/S 0.42
BASI's P/S is ranked higher than
93% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.95 vs. BASI: 0.42 )
Ranked among companies with meaningful P/S only.
BASI' s P/S Range Over the Past 10 Years
Min: 0.1  Med: 0.53 Max: 1.14
Current: 0.42
0.1
1.14
POCF 5.05
BASI's POCF is ranked higher than
95% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.45 vs. BASI: 5.05 )
Ranked among companies with meaningful POCF only.
BASI' s POCF Range Over the Past 10 Years
Min: 1.24  Med: 7.94 Max: 41.72
Current: 5.05
1.24
41.72
EV-to-EBIT 49.59
BASI's EV-to-EBIT is ranked lower than
89% of the 96 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.15 vs. BASI: 49.59 )
Ranked among companies with meaningful EV-to-EBIT only.
BASI' s EV-to-EBIT Range Over the Past 10 Years
Min: -105.7  Med: 11.30 Max: 221.4
Current: 49.59
-105.7
221.4
EV-to-EBITDA 8.73
BASI's EV-to-EBITDA is ranked higher than
79% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.21 vs. BASI: 8.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
BASI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -74  Med: 9.00 Max: 74.6
Current: 8.73
-74
74.6
Current Ratio 0.46
BASI's Current Ratio is ranked lower than
95% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. BASI: 0.46 )
Ranked among companies with meaningful Current Ratio only.
BASI' s Current Ratio Range Over the Past 10 Years
Min: 0.35  Med: 1.12 Max: 3.95
Current: 0.46
0.35
3.95
Quick Ratio 0.35
BASI's Quick Ratio is ranked lower than
95% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. BASI: 0.35 )
Ranked among companies with meaningful Quick Ratio only.
BASI' s Quick Ratio Range Over the Past 10 Years
Min: 0.24  Med: 0.81 Max: 3.05
Current: 0.35
0.24
3.05
Days Inventory 36.07
BASI's Days Inventory is ranked higher than
74% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 94.76 vs. BASI: 36.07 )
Ranked among companies with meaningful Days Inventory only.
BASI' s Days Inventory Range Over the Past 10 Years
Min: 22.9  Med: 29.38 Max: 36.89
Current: 36.07
22.9
36.89
Days Sales Outstanding 44.94
BASI's Days Sales Outstanding is ranked higher than
75% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. BASI: 44.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
BASI' s Days Sales Outstanding Range Over the Past 10 Years
Min: 37.96  Med: 53.30 Max: 81.92
Current: 44.94
37.96
81.92
Days Payable 78.86
BASI's Days Payable is ranked higher than
68% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 56.90 vs. BASI: 78.86 )
Ranked among companies with meaningful Days Payable only.
BASI' s Days Payable Range Over the Past 10 Years
Min: 18.44  Med: 31.55 Max: 87.14
Current: 78.86
18.44
87.14

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1.08
BASI's Price/Tangible Book is ranked higher than
93% of the 156 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.35 vs. BASI: 1.08 )
Ranked among companies with meaningful Price/Tangible Book only.
BASI' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.33  Med: 1.52 Max: 3.33
Current: 1.08
0.33
3.33
Price/Projected FCF 0.72
BASI's Price/Projected FCF is ranked higher than
96% of the 73 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. BASI: 0.72 )
Ranked among companies with meaningful Price/Projected FCF only.
BASI' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.33  Med: 1.04 Max: 63
Current: 0.72
0.33
63
Price/Median PS Value 0.77
BASI's Price/Median PS Value is ranked higher than
73% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. BASI: 0.77 )
Ranked among companies with meaningful Price/Median PS Value only.
BASI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.25  Med: 1.20 Max: 3.72
Current: 0.77
0.25
3.72
Earnings Yield (Greenblatt) (%) 1.98
BASI's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.40 vs. BASI: 1.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BASI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 3.50 Max: 20.5
Current: 1.98
0.5
20.5
Forward Rate of Return (Yacktman) (%) -8.72
BASI's Forward Rate of Return (Yacktman) (%) is ranked lower than
83% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.36 vs. BASI: -8.72 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BASI' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -11.6  Med: 6.90 Max: 34.5
Current: -8.72
-11.6
34.5

More Statistics

Revenue (TTM) (Mil) $21.36
EPS (TTM) $ -0.02
Beta0.14
Short Percentage of Float0.89%
52-Week Range $0.90 - 2.20
Shares Outstanding (Mil)8.11
» More Articles for BASI

Headlines

Articles On GuruFocus.com
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 09 2011 
Bioanalytical Systems Inc. Reports Operating Results (10-Q/A) May 20 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) May 17 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 16 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-K/A) Feb 10 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Aug 12 2009 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) May 18 2009 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 23 2009 

More From Other Websites
BIOANALYTICAL SYSTEMS INC Financials May 21 2016
Edited Transcript of BASI earnings conference call or presentation 12-May-16 3:00pm GMT May 18 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 10-Q, Quarterly Report May 16 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... May 13 2016
Bioanalytical Systems, Inc. :BASI-US: Earnings Analysis: Q2, 2016 By the Numbers May 13 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 12 2016
BASi Reports Second Quarter Results May 12 2016
Q2 2016 Bioanalytical Systems Inc Earnings Release - Before Market Open May 12 2016
Bioanalytical Systems, Inc. Announces Appointment of New Chief Financial Officer May 11 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... May 04 2016
Bioanalytical Systems to Release Second Quarter Fiscal 2016 Results on Thursday, May 12, 2016;... May 04 2016
Bioanalytical Systems to Release Second Quarter Fiscal 2016 Results on Thursday, May 12, 2016;... May 03 2016
BASi Launches New Website and E-Catalogue Apr 14 2016
CORRECTING and REPLACING BASi Introduces the Next Generation of Electrochemical Analyzer With the... Mar 29 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Mar 16 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 04 2016
Bioanalytical Systems, Inc. Earnings Analysis: Q1, 2016 By the Numbers Feb 18 2016
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 17 2016
Edited Transcript of BASI earnings conference call or presentation 16-Feb-16 4:00pm GMT Feb 17 2016
Bioanalytical Systems Loss Widens in Q1, Revenues Fall Feb 17 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)